Episode: LISTEN UP: DUCHENNE MUSCULAR DYSTROPHY: What happened to 20-year-old comparative data on two corticosteroids for Duchenne muscular dystrophy (DMD) — and what does it mean for the DMD therapy pipeline now?


Neurology Today - Neurology Today Podcast Logo
Subscribe
LISTEN UP: DUCHENNE MUSCULAR DYSTROPHY: What happened to 20-year-old comparative data on two corticosteroids for Duchenne muscular dystrophy (DMD) — and what does it mean for the DMD therapy pipeline now?
The Food and Drug Administration is considering a new drug application for deflazacort based on data from a 1995 study released in Neurology. Here, the senior study author Robert C. Griggs, MD, FAAN, professor of neurology, medicine, pediatrics, pathology & laboratory medicine in the Center for Human Experimental Therapeutics at the University of Rochester School of Medicine and Dentistry, discusses what the findings could mean for DMD therapy. For more about the study, read the Oct. 6 issue of Neurology Today: neurotodayonline.com.

Neurology Today - Neurology Today Podcast
Users who viewed this episode also viewed...

Neurology Today - Neurology Today Podcast > Dr. Reisa A. Sperling: The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease Trial

What could the findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease trial (A4) — a new secondary prevention trial in older people with amyloid accumulation at high risk for Alzheimer’s disease dementia — mean for Alzheimer’s disease? Earlier detection and possibly earlier intervention, according to the lead author of the A4 trial...

Neurology Today - Neurology Today Podcast > Dr. Sean J. Pittock Discusses Autoimmune Epilepsy

Sean J. Pittock, MD, an associate professor of neurology and co-director of the Neuroimmunology Laboratory at Mayo Clinic, and colleagues published an April 4 Neurology study on autoimmune epilepsy. The Mayo researchers found encouraging, but preliminary results for the use of immunotherapy in medically intractable patients with suspected autoimmune epilepsy...

Neurology Today - Neurology Today Podcast > Is thymectomy an effective option for myasthenia gravis (MG) patients?

The first randomized, placebo-controlled trial to examine that question suggests that it is. Neurology Today speaks with the study principals — Gil I. Wolfe, MD, FAAN, the Irvin and Rosemary Smith professor and chair in the department of neurology at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences of SUNY, and Gary Cutter, PhD, professor of biostatistics at University of Alabama at Birmingham School of Public Health, about the long road to providing class 1 evidence for the therapy...
Comments (0)

Login or Sign up to leave a comment.

Log in
Sign up

Be the first to comment.